medigraphic.com
ISSN 0188-2198 (Print)

2017, Number 3

<< Back Next >>

Rev Mex Cardiol 2017; 28 (3)

Strategic evaluation of silent myocardial ischemia in a group of patients with rheumatoid arthritis and traditional cardiovascular risk factors

Puente-Barragán AC, Santiago-Ramírez R, Valdés-Becerril G, Muñoz-López S, Martínez-Escobar MC, Delgado-Espejel LG

Language: English
References: 21
Page: 111-117
PDF size: 199.58 Kb.


ABSTRACT

Introduction: IHD has become an important long-term end point for RA patients independent of traditional CVRF. Therefore, cardiovascular injury and mortality might be due to the presence of a chronic systematic inflammatory response. Nonetheless, there is a gap in its diagnosis since symptoms remain silent until major events occur. Objective: We aimed to evaluate by gated single-photon emission computed tomography (g-SPECT). Myocardial perfusion in asymptomatic Mexican patients with RA and at least one traditional CVRF, and without history of angina. Patients and methods: A prospective study with a total number of 91 patients was conducted. We evaluated CVRF and RA characteristics. We non-invasively assessed them with g-SPECT to reveal ischemia, territories and severity. We calculated relative risks and 95% CI of ischemia given the associated variables. Results: 22 (24.2%) patients presented ischemia, half of them in the LAD territory. Regarding CVRF and disease’s characteristics; only smokers and patients under a steroid treatment were at more risk to present ischemia (0.49 [0.24 to 0.98] and 2.04 [1.01 to 4.14, respectively) with a p = 0.046. Conclusion: We have contributed with additional evidence to strategically diagnose IHD in patients with RA even if they have no symptoms and independently of the existence of cardiovascular risk factors to prevent and reduce cardiovascular mortality.


REFERENCES

  1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008; 59 (12): 1690-1697.

  2. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004; 109 (Suppl II): II2-II10.

  3. Singh RB, Mengi SA, Xu YJ, Arneja AS, Dhalla NS. Pathogenesis of atherosclerosis: a multifactorial process. Exp Clin Cardiol. 2002; 7 (1): 40-53.

  4. Del Rincón I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001; 44 (12): 2737-2745.

  5. ADA. Diabetes care. Diabetes Care. 2014; 37 (1): S21-S22.

  6. James PA, Oparil S, Carter BL, Cushman WC, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults. JAMA. 2014; 311 (5): 507-520.

  7. Van Riel PL, Schumacher HR Jr. How does one assess early rheumatoid arthritis in daily clinical practice? Best Pract Res Clin Rheumatol. 2001; 15 (1): 67-76.

  8. Casas J, Shah T, Hingorani A, Danesh J, Pepys M. C-reactive protein and coronary heart disease: a critical review. J Inrtern Med. 2008; 264 (4): 295-314.

  9. Kurec AS, Lifshitz MS. General concepts and administrative issues, Philadelphia: Saunders Elsevier, 2011.

  10. Hendel R, Corbett J, Cullom S, DePuey EG, Garcia EV, Bateman T. The value and practice of attenuation correction for myocardial perfusion SPECT imaging. a joint position statement from the American Society of Nuclear Cardiology and the Society of Nuclear Medicine. J Nucl Cardiol. 2002; 9: 135-143.

  11. Ryan T, Antman E, Brooks N. American College of Cardiology. [En línea]. [Último acceso: 28 October 2015] Available: http://www.acc.org/clinical/guidelines/nov96/1999/amipdf99.pdf

  12. Chin D, Battistoni A, Tocci G, Passerini J, Parati G, Volpe M. Non-invasive diagnostic testing for coronary artery disease in the hypertensive patient: Potential advanages of a risk estimation-based algorithm. Am J Hypertens. 2012; 25 (12): 1226-1235.

  13. Patt H, Bandgar T, Lila A, Shah N. Management issues with exogenous steroid therapy. Indian J Endocrinol Metab. 2013; 17 (3): 612-616.

  14. Wolfe F, Mitchell D, Dibley JS, Bloch D, Williams C. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994; 37: 481-494.

  15. Monson RR, Hall AP. Mortality among arthritics. J Chronic Dis. 1976; 29: 459-467.

  16. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365 (23): 2205-2219.

  17. Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care. 2012; 18: S295-S302.

  18. Peláez-Ballestas I, Sanin LH, Moreno-Montoya J, Álvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M et al. Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol Suppl. 2011; 86: 3-8.

  19. Goodson N, Marks J, Lunt M, Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis. 2005; 64: 1595-1601.

  20. Kaplan MJ. Cardiovascular complications of rheumatoid arthritis-assessment, prevention and treatment. Rheum Dis Clin North Am. 2010; 36 (2): 405-426.

  21. Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatopid arthritis: results from a community based study. Ann Rheum Dis. 2004; 63: 952-955.




2020     |     www.medigraphic.com